Adam S. Tolin is a Litigation associate whose areas of concentration include complex commercial litigation and product liability.
Mr. Tolin has significant experience at trial, having played a key role representing Philip Morris, AstraZeneca, and Wyeth in trials that all resulted in defense verdicts.
Most recently, Mr. Tolin was a key member of the trial team that, after a four-month trial, secured a defense verdict for Philip Morris USA, Inc., in a claim for more than $455 million in economic damages brought by 37 Missouri hospitals against six tobacco companies. The defense verdict was recognized by The American Lawyer as a “resounding victory” for Philip Morris. Mr. Tolin argued pre-trial motions, including motions to exclude certain plaintiffs’ experts and to bifurcate the trial, and argued evidentiary issues during trial. He also played a significant role readying the defense on the claim for economic damages, including preparing the first expert to testify for the defense.
Mr. Tolin played a significant role representing AstraZeneca in the Seroquel litigation, coordinating trial strategy and witness preparation across all aspects of the MDL and state litigations. In 2010, Mr. Tolin was a central member of the trial team that secured a defense verdict in the first trial out of more than 20,000 individual cases alleging that Seroquel causes diabetes. He argued evidentiary issues pre-trial and during trial, and was responsible for preparing company witnesses to testify at trial.
In addition, Mr. Tolin was a member of three different trial teams that received defense jury verdicts for Wyeth in In Re: Diet Drugs Litigation. He took depositions in those cases, argued motions, prepared core demonstrative exhibits, and was responsible for preparing expert witnesses to testify at trial.
He also first chaired two Section 1983 prisoner civil rights trials in federal court.